Procter & Gamble Health Share Price

Pharmaceuticals company Procter & Gamble Health announced Q3FY26 results Financial Highlights: The company’s Revenue from Operations for Q3FY26 stood at Rs 37,045 lakh, representing a marginal decrease of 0.91% on a QoQ basis compared to Rs 37,386 lakh in Q2FY26, and an increase of 19.12% on a YoY basis compared to Rs 31,099 lakh in Q3FY25. Total Income for the quarter ended March 31, 2026, was Rs 37,445 lakh, showing a decrease of 1.00% QoQ from Rs 37,822 lakh and an increase of 19.21% YoY from Rs 31,410 lakh. Profit Before Tax (PBT) for Q3FY26 was Rs 13,321 lakh, reflecting a growth of 22.41% QoQ from Rs 10,882 lakh and a significant growth of 69.63% YoY from Rs 7,853 lakh. Net Profit for the quarter reached Rs 9,460 lakh, an increase of 21.92% compared to Rs 7,759 lakh in the preceding quarter and a growth of 54.63% compared to Rs 6,118 lakh in the corresponding quarter of the previous year. Earnings per equity share (EPS) for Q3FY26 was Rs 56.99 (not annualised), compared to Rs 46.74 in Q2FY26 and Rs 36.86 in Q3FY25. Business Highlights: Segment Performance: The company has identified Pharmaceuticals as its single primary reportable segment in accordance with Ind AS 108. Dividend Recommendation: The Board of Directors has recommended a final dividend of Rs 45 per equity share (nominal value of Rs 10 each) for the financial year ended March 31, 2026. This is subject to the approval of shareholders at the ensuing 59th Annual General Meeting. Operational Structure: The company does not have any subsidiary, associate, or joint venture as of March 31, 2026. Labour Codes Update: The company evaluated the impact of the new Labour Codes (2020) and assessed that any incremental impact is not material, as the current salary structure is in line with the requirements. Milind Thatte, Managing Director, Procter & Gamble Health, said: “We delivered a strong year with consistent top-line and bottom-line growth. We continued to invest across the value chain to address the evolving needs of our consumers and healthcare professionals. These include superior innovations that are backed by science to help our consumers live healthier and more vibrant lives, and consumer communication initiatives, as well as strengthened go-to-market and supply chain capabilities. We are delivering sustainable, balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption, productivity, and an agile accountable organization.” Note: The company's financial year-end is in June month. Result PDF

• Trendlyne
• 1 week 6 days ago

The Mumbai-based vitamins and supplements maker reported a 21% surge in sales to 368 crore for the quarter ended December 31, 2025, compared to 310 crore in the same period last year

• Business Line
• 4 months ago

Pharmaceuticals company Procter & Gamble Health announced Q3FY26 results Revenue: Rs 37,386 lakh against Rs 30,977 lakh during Q3FY25, change 21%. PBT: Rs 10,882 lakh against Rs 12,169 lakh during Q3FY25, change -11%. PAT: Rs 7,759 lakh against Rs 9,090 lakh during Q3FY25, change -15%. EPS: Rs 46.74 for Q3FY26. Milind Thatte, Managing Director, P&G; Health, said: “We delivered a strong top-line growth in the quarter, continuing the momentum from the first half of the financial year. This comes behind our strategic efforts across the value chain, including new innovations like Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream, and strengthening of supply chain capabilities. We remain committed towards addressing the evolving needs of our consumers, customers and healthcare professionals, via superior brand building, go to market initiatives, and innovations backed by science to help our consumers live healthier and more vibrant lives. We are delivering sustainable, balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption and an agile accountable organization.” The Company has declared an interim dividend of Rs 160 per equity share (including one-time special dividend of Rs 50 per share) for the FY26. Result PDF

• Trendlyne
• 4 months ago